GLP‑1 medications continue to transform obesity and metabolic care—and now, for the first time, the FDA has approved a semaglutide pill for weight management. While this expands access, it also raises important questions about cost, safety, compounding, and the future of generics. At Libélula Primary Care, we believe patients deserve clear, evidence‑based guidance to make informed decisions.